Aiforia has been named a top market player. The translation is from LinkedIn. The poster is a PR firm for a market research company. Such reports do not automatically carry the same level of reliability as the aforementioned scientific article in a decent-tier journal (even if it was funded by Big Pharma, AstraZeneca). And ranking at the top does not yet reveal anything about the absolute distribution of euros, but it does provide visibility and is a form of recognition. Those interested can provide their details there to get the full report and see the criteria in more detail. AI in Pathology Market to Reach $347.4M by 2030 | Healthcare Industry News Julkaistu aiheesta | LinkedIn
Aiforia’s previous revenue target of €100 million was, in the H1 review, calculated based on 50 potentially €500k customers in 2030. If the market research forecast for the “AI in pathology” market of $347.4 million by 2030 holds true (Aiforia’s slide even cited a source for that figure, the well-regarded Signify Research, Digital Pathology World), Aiforia would need to capture a bit less than a 10% share. That might not be impossible with “top player” status, especially if, alongside those large consolidations, they also acquire smaller clients, Pharma customers, predictive models, and expand their products beyond their current diagnostic support—as Aiforia communicates in its strategy (the aforementioned slides from 3 days ago).
